PDCD1 and hepatocellular carcinoma: The GEMINI-Hepatobiliary phase II study has a platform design and includes an HCC cohort testing of volrustomig (anti-PD-1/CTLA-4 bsAb) as a monotherapy or in combination with bevacizumab or Lenvatinib [121].